Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VIR Vir Biotechnology, Inc.

Closed 11-22 16:00:00 EST

7.12

+0.17

+2.45%

盘后7.12

+0.000.00%

19:42 EST

High7.27	Low6.88	Vol891.74K
Open7.00	D1 Closing6.95	Amplitude5.61%
Mkt Cap980.57M	Tradable Cap658.71M	Total Shares137.72M
T/O6.36M	T/O Rate0.96%	Tradable Shares92.52M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"VIR","market":"US","secType":"STK","nameCN":"Vir Biotechnology, Inc.","latestPrice":7.12,"timestamp":1732309200000,"preClose":6.95,"halted":0,"volume":891741,"hourTrading":{"tag":"盘后","latestPrice":7.12,"preClose":7.12,"latestTime":"19:42 EST","volume":35679,"amount":254036.01,"timestamp":1732322541668},"delay":0,"floatShares":92515983,"shares":137720120,"eps":-3.934819,"marketStatus":"Closed","change":0.17,"latestTime":"11-22 16:00:00 EST","open":7,"high":7.27,"low":6.88,"amount":6363367.467972,"amplitude":0.056115,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.934819,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732525200000},"marketStatusCode":5,"adr":0,"listingDate":1570766400000,"exchange":"NASDAQ","adjPreClose":6.95,"preHourTrading":{"tag":"盘前","latestPrice":6.95,"preClose":6.95,"latestTime":"09:12 EST","volume":74,"amount":523.310018,"timestamp":1732284735332},"postHourTrading":{"tag":"盘后","latestPrice":7.12,"preClose":7.12,"latestTime":"19:42 EST","volume":35679,"amount":254036.01,"timestamp":1732322541668},"volumeRatio":0.476895,"impliedVol":1.2776,"impliedVolPercentile":0.9802},"requestUrl":"/m/hq/s/VIR","defaultTab":"news","newsList":[{"id":"2484419078","title":"TD Cowen Keeps Their Buy Rating on Vir Biotechnology (VIR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2484419078","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484419078?lang=en_us&edition=fundamental","pubTime":"2024-11-20 20:26","pubTimestamp":1732105610,"startTime":"0","endTime":"0","summary":"In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Vir Biotechnology (VIR – Research Report). The company’s shares cl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-vir-biotechnology-vir?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-vir-biotechnology-vir?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COWN","VIR","TD"],"gpt_icon":0},{"id":"2484827167","title":"Vir Biotechnology Price Target Maintained With a $19.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2484827167","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484827167?lang=en_us&edition=fundamental","pubTime":"2024-11-20 17:41","pubTimestamp":1732095660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VIR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 20, 2024 04:41 ET (09:41 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR"],"gpt_icon":0},{"id":"2484598154","title":"U.S. RESEARCH ROUNDUP- Apellis Pharmaceuticals, Energizer Holdings, Walmart","url":"https://stock-news.laohu8.com/highlight/detail?id=2484598154","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484598154?lang=en_us&edition=fundamental","pubTime":"2024-11-20 14:56","pubTimestamp":1732085764,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Apellis Pharmaceuticals, Energizer Holdings, WalmartNov 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nL4N3MR0EQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABUS","NUVL","LU1551013425.SGD","LU2286300806.USD","SWTX","CRM","PBF","IE00BZ1G4Q59.USD","ENR","CHRD","LU0006061336.USD","BERY","OCSL","BK4086","MNPR","LU0265550946.USD","AZEK","NOG","VVV","LU0310799852.SGD","BBIO","TVTX","LU1066053197.SGD","VIR","OLMA","LU1267930490.SGD","BK4505","LOW","VERA","FSUN","APLS","BK4528","LU1988902786.USD","BK4596","IE00B19Z8X17.USD","PIII","BK4579","DYN","ANNX","BRBR","LH","LU2430703251.USD","IIIV","BK4187","LU2756315318.SGD","WMT","LU1951198990.SGD","CASY","LU0528227936.USD","AVAV"],"gpt_icon":1},{"id":"2484644912","title":"Vir Biotechnology announces results from SOLSTICE  trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2484644912","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484644912?lang=en_us&edition=fundamental","pubTime":"2024-11-19 19:21","pubTimestamp":1732015265,"startTime":"0","endTime":"0","summary":"Vir Biotechnology (VIR) announced results from the SOLSTICE Phase 2 clinical trial evaluating tobevibart alone, or in combination with elebsiran, i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vir-biotechnology-announces-results-from-solstice-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vir-biotechnology-announces-results-from-solstice-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","BK4139","BK4535","BK4585","VIR"],"gpt_icon":0},{"id":"2484955228","title":"BRIEF-Vir Biotechnology Says Tobevibart And Elebsiran Achieve 100% Virologic Suppression At Week 24","url":"https://stock-news.laohu8.com/highlight/detail?id=2484955228","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484955228?lang=en_us&edition=fundamental","pubTime":"2024-11-19 10:16","pubTimestamp":1731982580,"startTime":"0","endTime":"0","summary":"Nov 18  - Vir Biotechnology Inc   :   * VIR BIOTECHNOLOGY PRESENTS POSITIVE CHRONIC HEPATITIS DELTA CLINICAL TRIAL DATA AND ANNOUNCES INITIATION OF PHASE 3 REGISTRATIONAL PROGRAM   * VIR BIOTECHNOLOGY INC - TOBEVIBART AND ELEBSIRAN ACHIEVE 100% VIROLOGIC SUPPRESSION AT WEEK 24   * VIR BIOTECHNOLOGY INC - PHASE 3 ECLIPSE PROGRAM TO EVALUATE TOBEVIBART AND ELEBSIRAN   * VIR BIOTECHNOLOGY INC - PHASE 3 ECLIPSE PROGRAM TO BEGIN IN FIRST HALF OF 2025   * VIR BIOTECHNOLOGY INC - EMA ISSUES POSITIVE OPINION ON ORPHAN DRUG DESIGNATION FOR TOBEVIBART AND ELEBSIRANSource text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4585","BK4535","VIR","BK4139"],"gpt_icon":0},{"id":"2484955269","title":"Vir Biotechnology Inc - Ema Issues Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran","url":"https://stock-news.laohu8.com/highlight/detail?id=2484955269","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484955269?lang=en_us&edition=fundamental","pubTime":"2024-11-19 10:15","pubTimestamp":1731982501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nTUA8F0NGF:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","BK4139","VIR","BK4535","BK4585"],"gpt_icon":0},{"id":"2484955266","title":"Vir Biotechnology Inc - Phase 3 Eclipse Program to Begin in First Half of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2484955266","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484955266?lang=en_us&edition=fundamental","pubTime":"2024-11-19 10:15","pubTimestamp":1731982501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nTUA8F0NGF:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4568","VIR","BK4585","BK4535"],"gpt_icon":0},{"id":"2484955264","title":"Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2484955264","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484955264?lang=en_us&edition=fundamental","pubTime":"2024-11-19 10:15","pubTimestamp":1731982501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nTUA8F0NGF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VIR","BK4139","BK4535","BK4568","BK4585"],"gpt_icon":0},{"id":"2484552619","title":"Vir Biotechnology Inc - Tobevibart and Elebsiran Achieve 100% Virologic Suppression at Week 24","url":"https://stock-news.laohu8.com/highlight/detail?id=2484552619","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484552619?lang=en_us&edition=fundamental","pubTime":"2024-11-19 10:15","pubTimestamp":1731982501,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241119:nTUA8F0NGF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4535","BK4585","BK4568","VIR"],"gpt_icon":0},{"id":"2484956973","title":"Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2484956973","media":"Business Wire","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484956973?lang=en_us&edition=fundamental","pubTime":"2024-11-19 10:15","pubTimestamp":1731982500,"startTime":"0","endTime":"0","summary":"– Monthly tobevibart and elebsiran combination achieves rapid 100% virologic suppression at Week 24, sustained through Week 60 –。– Undetectable HDV RNA in 41% of participants at Week 24, increasing to 64% by Week 36 and up to 80% by Week 60 across cohorts –。– Combination well-tolerated: no treatment-related severe AEs, treatment-related discontinuations or ALT flares –。– Following a recent FDA meeting, Phase 3 ECLIPSE registrational program to begin in the first half of 2025 –。These data were presented in an oral session at the American Association for the Study of Liver Diseases  The Liver Meeting, in San Diego, CA. Based on these results, and following a recent meeting with the FDA, Vir Biotechnology plans to initiate the Phase 3 registrational ECLIPSE program in the first half of 2025 to further evaluate the combination of tobevibart and elebsiran for the treatment of CHD.Primary Endpoint Analysis from the Phase 2 SOLSTICE Tria","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/l5oi2o6BXS3LWePoIaxyng--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4cd04e41299f5f946a2db3e8d5341040","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/l5oi2o6BXS3LWePoIaxyng--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/4cd04e41299f5f946a2db3e8d5341040"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vir-biotechnology-presents-positive-chronic-021500234.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4568","BK4585","BK4539","CHD","ALT","BK4588","COMP","HDV","LU1878469433.USD","VIR","BK4535","BK4018","RNA","BK4504","BK4505","BK4079"],"gpt_icon":0},{"id":"2484878659","title":"Vir Biotechnology Prospective Treatment for Hepatitis Delta Gets EU Advisory Committee Recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2484878659","media":"MT Newswires Live","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484878659?lang=en_us&edition=fundamental","pubTime":"2024-11-19 06:10","pubTimestamp":1731967821,"startTime":"0","endTime":"0","summary":"Vir Biotechnology  late Monday said European regulators are expected to approve its product candidates to treat a relatively rare form of hepatitis and liver disease as an orphan drug.A European Medicines Agency advisory panel recommended approving tobevibart and elebsiran as an orphan drug for the treatment of chronic hepatitis delta. The recommendation follows encouraging preliminary data from a phase 2 trial evaluating the efficacy of the drug combination in adults with hepatitis delta infections.The US Food and Drug Administration in June issued a fast-track designation for the tobevibart and elebsirann, which will expedite the review process.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VIR","BK4535","BK4585","BK4568","BK4156","BK4139"],"gpt_icon":0},{"id":"2484898900","title":"Vir Biotechnology gets positive opinion on orphan drug designation for Tobevibar","url":"https://stock-news.laohu8.com/highlight/detail?id=2484898900","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484898900?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:10","pubTimestamp":1731964244,"startTime":"0","endTime":"0","summary":"Vir Biotechnology (VIR) “announced that the European Medicines Agency Committee for Orphan Medicinal Products, has issued a positive opinion on the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vir-biotechnology-gets-positive-opinion-on-orphan-drug-designation-for-tobevibar?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vir-biotechnology-gets-positive-opinion-on-orphan-drug-designation-for-tobevibar?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4535","BK4139","BK4568","VIR"],"gpt_icon":0},{"id":"2484591989","title":"Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta From European Medicines Agency","url":"https://stock-news.laohu8.com/highlight/detail?id=2484591989","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484591989?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:06","pubTimestamp":1731963993,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241118:nFWN3MP1C4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4535","BK4585","VIR","BK4568"],"gpt_icon":0},{"id":"2484987837","title":"Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency","url":"https://stock-news.laohu8.com/highlight/detail?id=2484987837","media":"Business Wire","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484987837?lang=en_us&edition=fundamental","pubTime":"2024-11-19 05:05","pubTimestamp":1731963900,"startTime":"0","endTime":"0","summary":"– Orphan designation in E.U. supports development of treatments for life-threatening or chronically debilitating conditions with significant unmet medical need –。– Phase 2 SOLSTICE 24-week primary endpoint data for tobevibart and elebsiran in chronic hepatitis delta to be presented today at AASLD The Liver Meeting –。SAN FRANCISCO, November 18, 2024----Vir Biotechnology, Inc.  today announced that the European Medicines Agency  Committee for Orphan Medicinal Products , has issued a positive opinion on the application for orphan drug designation of tobevibart and elebsiran for the treatment of chronic hepatitis delta . This opinion is based on encouraging preliminary data from the Phase 2 SOLSTICE trial. Vir Biotechnology will present 24-week data from the Phase 2 SOLSTICE trial at AASLD The Liver Meeting in San Diego, CA, on November 18 at 6.15 p.m. PT. An investor conference call is scheduled for November 19, 2024, at 5.15 a.m. PT / 8.15 a.m. ET.In June 2024, the U.S. Food and Drug Adm","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7t3Zh_oOq.Ev7QwyfJfJ7A--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c6e8102cbc679b8da4fd51cdf0d22878","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7t3Zh_oOq.Ev7QwyfJfJ7A--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/c6e8102cbc679b8da4fd51cdf0d22878"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vir-biotechnology-receives-positive-opinion-210500380.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4504","BK4588","COMP","BK4539","LU1878469433.USD","BK4585","BK4568","HDV","BK4018","BK4535","ALT","MDCO","VIR","CHD","BK4139","BK4079"],"gpt_icon":0},{"id":"2483585749","title":"What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2483585749","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483585749?lang=en_us&edition=fundamental","pubTime":"2024-11-16 02:39","pubTimestamp":1731695973,"startTime":"0","endTime":"0","summary":"On Friday, Vir Biotechnology, Inc.  announced end-of-treatment data from Part B of the MARCH Phase 2 study evaluating combinations of tobevibart and elebsiran, with or without pegylated interferon alfa , in participants with chronic hepatitis B.Chronic hepatitis B  is a long-lasting, inflammatory liver disease caused by the hepatitis B virus .The World Health Organization estimates that 254 million people live with CHB, and an estimated 1.1 million yearly deaths are associated with the disease.Also Read: Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?The study demonstrated promising rates of hepatitis B surface antigen  loss  in participants with low baseline HBsAg  in both combination regimens.The doublet and triplet regimens resulted in HBsAg loss at the end of treatment in 39%  and 46%  of participants with baseline HBsAg<1,000 IU/mL, respectively.The proportion of participants with varying baseline HBsAg levels who achieved HBsAg loss at the e","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OwcgwHvIAPvIG9fTP4OW9Q--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/af5e8ee44c196e5291b0d9390662a895","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OwcgwHvIAPvIG9fTP4OW9Q--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/af5e8ee44c196e5291b0d9390662a895"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/whats-going-liver-disease-focused-183933781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CHB","BK4568","BK4535","BK4585","BK4139","VIR"],"gpt_icon":0},{"id":"2483309206","title":"Vir Biotechnology reports ‘positive’ end-of-treatment data from MARCH study","url":"https://stock-news.laohu8.com/highlight/detail?id=2483309206","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483309206?lang=en_us&edition=fundamental","pubTime":"2024-11-16 00:05","pubTimestamp":1731686724,"startTime":"0","endTime":"0","summary":"Vir Biotechnology (VIR) announced end-of-treatment data from Part B of the MARCH Phase 2 clinical study evaluating combinations of tobevibart and e...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vir-biotechnology-reports-positive-end-of-treatment-data-from-march-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vir-biotechnology-reports-positive-end-of-treatment-data-from-march-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4568","BK4535","VIR","BK4139","BK4585"],"gpt_icon":0},{"id":"2483093543","title":"Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2483093543","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483093543?lang=en_us&edition=fundamental","pubTime":"2024-11-16 00:00","pubTimestamp":1731686400,"startTime":"0","endTime":"0","summary":"– 39% of participants with low baseline Hepatitis B surface antigen  achieved HBsAg loss with tobevibart + elebsiran, and 46% with tobevibart + elebsiran + pegylated interferon alfa –。– No new safety concerns were identified, and treatment-emergent adverse events were generally mild to moderate –。The doublet and triplet regimens resulted in HBsAg loss at the end of treatment in 39%  and 46%  of participants with baseline HBsAg<1,000 IU/mL, respectively. The proportion of participants with varying baseline HBsAg levels who achieved HBsAg loss at end of treatment was 16%  for the doublet and 22%  for the triplet regimen. The doublet regimen resulted in 50% (4/8) of participants who had achieved HBsA","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BwGTHeP9qdhUlV7fCpxUmA--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/b4eff3a25200b618dc1011796efb03c1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BwGTHeP9qdhUlV7fCpxUmA--~B/aD0yMzM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/b4eff3a25200b618dc1011796efb03c1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vir-biotechnology-announces-positive-end-160000726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CHB","BK4568","BK4139","BK4535","BK4585","VIR"],"gpt_icon":0},{"id":"2481726626","title":"Analysts Conflicted on These Healthcare Names: Vir Biotechnology (VIR) and Moderna (MRNA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2481726626","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481726626?lang=en_us&edition=fundamental","pubTime":"2024-11-06 16:30","pubTimestamp":1730881808,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vir Biotechnology (VIR – Research Report) and Moderna (MRNA – Res...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-vir-biotechnology-vir-and-moderna-mrna?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-vir-biotechnology-vir-and-moderna-mrna?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNA","BK4532","BK4534","BK4551","BK4137","HCSG","BK4139","BK4568","BK4548","BK4585","BK4588","BK4501","VIR","BK4533","BK4535"],"gpt_icon":0},{"id":"2480079304","title":"Vir Biotechnology Is Maintained at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2480079304","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480079304?lang=en_us&edition=fundamental","pubTime":"2024-11-04 20:28","pubTimestamp":1730723280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VIR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 04, 2024 07:28 ET (12:28 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR"],"gpt_icon":0},{"id":"2480306349","title":"Vir Biotechnology Price Target Maintained With a $110.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2480306349","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2480306349?lang=en_us&edition=fundamental","pubTime":"2024-11-04 19:31","pubTimestamp":1730719860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VIR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 04, 2024 06:31 ET (11:31 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vir.bio","stockEarnings":[{"period":"1week","weight":-0.1956},{"period":"1month","weight":-0.0867},{"period":"3month","weight":-0.2075},{"period":"6month","weight":-0.3412},{"period":"1year","weight":-0.2937},{"period":"ytd","weight":-0.3091}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.0177},{"period":"3month","weight":0.0561},{"period":"6month","weight":0.1213},{"period":"1year","weight":0.3047},{"period":"ytd","weight":0.249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.489907},{"month":2,"riseRate":0.4,"avgChangeRate":0.083527},{"month":3,"riseRate":0.4,"avgChangeRate":-0.100299},{"month":4,"riseRate":0.2,"avgChangeRate":-0.094284},{"month":5,"riseRate":0.8,"avgChangeRate":0.108172},{"month":6,"riseRate":0.4,"avgChangeRate":0.019995},{"month":7,"riseRate":0.6,"avgChangeRate":-0.054563},{"month":8,"riseRate":0.2,"avgChangeRate":-0.028112},{"month":9,"riseRate":0,"avgChangeRate":-0.169768},{"month":10,"riseRate":0.2,"avgChangeRate":-0.046173},{"month":11,"riseRate":0.666667,"avgChangeRate":0.08781},{"month":12,"riseRate":0.4,"avgChangeRate":-0.053554}],"exchange":"NASDAQ","name":"Vir Biotechnology, Inc.","nameEN":"Vir Biotechnology, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vir Biotechnology, Inc.(VIR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vir Biotechnology, Inc.,VIR,Vir Biotechnology, Inc.股票,Vir Biotechnology, Inc.股票老虎,Vir Biotechnology, Inc.股票老虎国际,Vir Biotechnology, Inc.行情,Vir Biotechnology, Inc.股票行情,Vir Biotechnology, Inc.股价,Vir Biotechnology, Inc.股市,Vir Biotechnology, Inc.股票价格,Vir Biotechnology, Inc.股票交易,Vir Biotechnology, Inc.股票购买,Vir Biotechnology, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vir Biotechnology, Inc.(VIR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vir Biotechnology, Inc.(VIR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction